U.S. Cardiac Rhythm Management Devices Market (2025 - 2033)

Market Size & Trends

The U.S. cardiac rhythm management devices market size was estimated at USD 6.8 billion in 2024 and is projected to grow at a CAGR of 6.6% from 2025 to 2033. The U.S. cardiac rhythm management market is advancing through a convergence of growing clinical demand, evolving device technologies, and greater integration of remote care. Companies are aligning product strategies with these shifts, emphasizing miniaturization, connectivity, and continuous monitoring to support both acute and long-term patient management.

In May 2024, Defibtech expanded its Lifeline VIEW and ECG defibrillator lines in the U.S. by launching dual-language AED models with English and Spanish toggle features. These updates aim to improve accessibility and usability for diverse responders during sudden cardiac emergencies.

The increasing burden of arrhythmias and heart failure in the U.S. is accelerating the demand for cardiac rhythm management devices. An aging population combined with a rise in comorbidities such as hypertension, obesity, and diabetes is creating a steady need for reliable long-term cardiac interventions. Devices such as pacemakers, defibrillators, and resynchronization systems are becoming critical tools in managing chronic cardiac conditions and preventing sudden cardiac death. In September 2024, researchers from the University of California, San Francisco published a study in the Journal of the American College of Cardiology estimating that atrial fibrillation affects 10.55 million U.S. adults. The analysis, based on over 29 million hospital records in California from 2005-2019, revealed that current prevalence is nearly triple the earlier estimates and increasingly affects younger, more diverse populations.

Prevalence of heart failure in Americans over 20 years of age

Source: Journal of Cardiac Failure

Heart failure is a chronic, progressive condition marked by the heart's inability to pump blood effectively, often resulting in hospitalizations, reduced quality of life, and high mortality. It places a growing burden on healthcare systems, especially with aging populations and rising comorbidities such as diabetes and hypertension. Device-based interventions, including cardiac rhythm management and lead management systems, are increasingly essential for early diagnosis, stabilization, and long-term care in heart failure patients. In January 2025, according to the Heart Failure Society of America, around 6.7 million U.S. adults over 20 have heart failure, with prevalence projected to reach 8.7 million by 2030, 10.3 million by 2040, and 11.4 million by 2050.

Advances in device engineering are reshaping the market, particularly with the emergence of leadless and wireless technologies. Leadless pacemakers reduce complications associated with conventional systems and simplify implantation, while wireless platforms improve communication and synchronization. These enhancements offer greater safety, ease of use, and long-term reliability, making them increasingly attractive in both hospital and ambulatory settings. In April 2025, Medtronic gained FDA clearance for the OmniaSecure, a miniaturized defibrillation lead tailored for implantable cardioverter-defibrillator systems. Its compact 4.7 French size supports accurate placement while lowering the chance of vascular or valve complications. Findings from the LEADR trial, shared at Heart Rhythm 2025, reported full defibrillation success at implantation.

The integration of remote monitoring into cardiac care workflows is driving further adoption across healthcare providers. Real-time data transmission from implanted devices enables early detection of arrhythmias and device performance issues, reducing unplanned interventions and supporting proactive care models. This capability also aligns with broader digital health strategies and payer interest in minimizing costly hospital visits. In March 2025, MicroPort CRM launched the SmartView Connect App Mobile in Europe after receiving CE mark approval. The Android app links Bluetooth-enabled pacemakers to clinics, enabling secure remote monitoring without bedside monitors for bradycardia patients.

Market Concentration & Characteristics

The degree of innovation in the U.S. cardiac rhythm management devices industry is high, driven by rapid advancements in leadless technologies, wireless communication, and integration with digital health platforms. Innovations such as AI-based arrhythmia detection, longer battery life, and MRI-safe components are becoming central to competitive differentiation. In May 2025, ZOLL Medical presented results from the SCD-PROTECT study at ESC Heart Failure, covering over 19,000 LifeVest patients in Germany. Despite widespread use of contemporary GDMT, high rates of appropriate LifeVest treatments were observed, underscoring elevated short-term SCD risk.

The level of mergers and acquisitions is moderate in the U.S. cardiac rhythm management devices industry, with strategic consolidation primarily aimed at expanding portfolios, acquiring specialized technologies, and enhancing market access. While the market is led by a few dominant players, M&A activity is often focused on emerging startups offering niche innovations or complementary remote monitoring solutions. In September 2024, Merit Medical announced a USD 210 million acquisition of Cook Medical’s lead management portfolio, aiming to expand its cardiac rhythm and electrophysiology segment. The acquired products, used in pacemaker and defibrillator lead removal, are expected to add USD 40 million in annual sales.

The impact of regulations on the U.S. cardiac rhythm management devices industry is high, given the critical nature of the products and the need for stringent safety, efficacy, and performance standards. Regulatory shifts toward real-world evidence, cybersecurity compliance, and post-approval monitoring are adding complexity to market entry and lifecycle management, especially for novel device formats. In October 2023, Medtronic gained FDA approval for the Aurora EV-ICD system, the first extravascular defibrillator with ATP and backup pacing. It places leads outside the heart and veins to reduce complications. The device showed 98.7% effectiveness at implant and has a projected 11.7-year battery life.

The level of product substitution in the U.S. cardiac rhythm management devices industry remains low, as alternatives to implantable or external CRM devices are limited. Pharmacologic or non-invasive therapies may offer support but cannot replicate the core functionalities of pacing, defibrillation, or resynchronization, keeping device dependence strong across clinical settings.

Product Insights

The defibrillators segment held the largest revenue share of 24.5% in 2024. This dominance is attributed to its critical role in managing life-threatening arrhythmias and sudden cardiac arrest. High prevalence of cardiovascular conditions, growing emphasis on preventive care, and widespread use of implantable cardioverter defibrillators (ICDs) in both hospital and ambulatory settings have reinforced demand. Continued innovation in subcutaneous and wearable defibrillator formats, combined with strong clinical adoption and reimbursement support, has further solidified the segment’s leading position. In May 2025, Element Science secured FDA approval for its Jewel Patch-Wearable Cardioverter Defibrillator, a next-generation device designed for patients at temporary risk of sudden cardiac arrest. The device integrates AI-driven arrhythmia detection with a discreet, water-resistant design, enabling continuous use during daily activities.

The cardiac resynchronization therapy (CRT) segment is expected to grow at the fastest CAGR over the forecast period, driven by its expanding use in treating heart failure patients with electrical dyssynchrony. Increasing clinical recognition of CRT’s ability to improve cardiac output, reduce hospitalization, and enhance quality of life is driving wider adoption. Advancements in device programming, quadripolar lead systems, and non-invasive implantation techniques are also making CRT more accessible across varied patient risk profiles, supporting sustained growth momentum. In April 2025, EBR Systems received FDA approval for its WiSE CRT System, the world’s first leadless solution for left ventricular endocardial pacing. The device targets patients unsuitable for traditional CRT due to lead-related complications. A limited U.S. market release is planned for late 2025, with full commercialization expected in early 2026.

Key U.S. Cardiac Rhythm Management Devices Company Insights

Some of the key market players operating in the U.S. cardiac rhythm management devices industry include companies such as Medtronic, Boston Scientific Corporation, Abbott, Schiller AG, and Koninklijke Philips N.V. that focus on miniaturized implantable technologies, remote monitoring capabilities, and algorithm-driven arrhythmia detection. These companies invest in extending battery life, enhancing MRI compatibility, and integrating devices with digital health platforms. While established players drive innovation in leadless pacing and subcutaneous defibrillators, emerging companies target niche clinical needs with specialized systems and streamlined regulatory strategies to maintain a competitive edge.

Recent Developments

• In June 2025, ZOLL Medical partnered with Simon’s Heart to donate AED 3 defibrillators to 32 youth organizations across the U.S. The initiative supports CPR and AED training to protect young athletes from sudden cardiac arrest. Devices were distributed to Boys & Girls Clubs and youth football teams lacking existing AED access.

• In April 2025, Northwestern introduced a light-activated injectable pacemaker, smaller than a grain of rice, that dissolves in the body after use. Ideal for newborns needing temporary pacing, it pairs with a wearable patch to deliver infrared-triggered heart stimulation without surgery.

• In December 2024, Abbott completed the world’s first implantation of a leadless pacemaker in the left bundle branch area using its AVEIR CSP system. This novel approach merges conduction system pacing with leadless technology to closely mimic natural heart rhythms and reduce long-term complications.

• In June 2024, Stryker launched the LIFEPAK 35 monitor/defibrillator, built for advanced life support in critical cardiac events. With a slim design, intuitive touchscreen, and integrated data connectivity, it streamlines workflows and supports rapid clinical decisions. Backed by a decade of research, it’s tailored for high-pressure hospital and EMS settings.

U.S. Cardiac Rhythm Management Devices Market